RLS-0071 for Graft-versus-Host Disease
(AURORA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment called RLS-0071 for individuals with acute Graft-versus-Host Disease (aGvHD), a serious condition that can occur after a bone marrow transplant. The trial aims to assess the safety and effectiveness of RLS-0071 for those who do not respond to steroids. Participants will receive varying doses of RLS-0071, sometimes in combination with another drug, ruxolitinib, to determine the optimal dosing strategy. The trial seeks hospitalized patients with steroid-resistant aGvHD post-transplant, who are expected to remain in the hospital for at least a week. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group of participants.
Do I need to stop my current medications for this trial?
The trial does not specify if you need to stop your current medications, but it does require that you do not add, adjust, or stop any GvHD prophylactic medications during the 7-day treatment with RLS-0071.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that RLS-0071, also known as pegtarazimod, appears safe for treating acute Graft-versus-Host Disease (aGvHD). Although detailed safety data from human trials is not yet available, earlier animal studies showed good results. These studies suggest that the treatment is generally well-tolerated, with no serious side effects observed.
Additionally, the European Medicines Agency has granted RLS-0071 orphan drug status. This designation is often given to treatments that could benefit rare conditions, suggesting its potential safety. The current trial's advanced stage indicates that earlier studies did not find major safety issues. However, individual reactions to medical treatments can vary.12345Why are researchers excited about this trial's treatments?
RLS-0071 is unique for treating graft-versus-host disease because it targets the underlying inflammation differently. While most current treatments, like steroids and immunosuppressants such as ruxolitinib, broadly suppress the immune system, RLS-0071 specifically aims to modulate the inflammatory pathways more precisely, potentially reducing side effects. Researchers are excited about RLS-0071 because it may offer a more targeted approach, which could lead to better outcomes and improved quality of life for patients with fewer complications.
What evidence suggests that this trial's treatments could be effective for acute Graft-versus-Host Disease?
Research has shown that RLS-0071, also known as pegtarazimod, may help treat acute Graft-versus-Host Disease (aGvHD), especially when steroids are no longer effective. In animal studies, RLS-0071 significantly improved survival rates. This treatment reduces inflammation, a major issue in aGvHD. In this trial, some participants will receive RLS-0071 alone, while others will receive it in combination with ruxolitinib to evaluate if the combination is even more effective. The European Medicines Agency has recognized its potential by granting it orphan drug status, highlighting its importance for this condition.12467
Are You a Good Fit for This Trial?
This trial is for hospitalized adults and adolescents over 12 years old, weighing between 40-140 kg, with grade II-IV acute Graft-versus-Host Disease that hasn't improved with steroids. Participants must have recovered neutrophils after a stem-cell transplant and expect to stay in the hospital for at least one week.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive RLS-0071 in various dosing regimens for 7 to 14 days, with some cohorts receiving concurrent ruxolitinib
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- RLS-0071
Trial Overview
The study tests RLS-0071's safety and effectiveness as a secondary treatment for steroid-refractory acute Graft-versus-Host Disease. It involves varying doses of RLS-0071 to find the right balance between efficacy and tolerability.
How Is the Trial Designed?
7
Treatment groups
Experimental Treatment
10 mg/kg Q8H RLS-0071 for 7 days
12 participants will receive 20 mg/kg Q8H RLS-0071 for 14 days
12 participants will receive 10 mg/kg Q8H RLS-0071 for 14 days
20 mg/kg Q8H RLS-0071 for 7 days and then 20 mg/kg QD RLS-0071 for 7 days with concurrent ruxolitinib
10 mg/kg Q8H RLS-0071 for 7 days and then 10 mg/kg QD RLS-0071 for 7 days with concurrent ruxolitinib
20 mg/kg Q8H RLS-0071 for 14 days with concurrent ruxolitinib
10 mg/kg Q8H RLS-0071 for 14 days with concurrent ruxolitinib
Find a Clinic Near You
Who Is Running the Clinical Trial?
ReAlta Life Sciences, Inc.
Lead Sponsor
CTI Clinical Trial and Consulting Services
Collaborator
Citations
1.
realtalifesciences.com
realtalifesciences.com/news/realta-announces-positive-preclinical-data-for-rls-0071-pegtarazimod-in-acute-graft-versus-host-disease-at-american-society-of-hematology-annual-meeting/Data demonstrates pegtarazimod's ...
ReAlta Life Sciences Announces Positive Preclinical Data for RLS-0071 (pegtarazimod) in Acute Graft-Versus-Host Disease (aGVHD) at American ...
2.
ashpublications.org
ashpublications.org/blood/article/144/Supplement%201/3399/533360/Exploring-a-Novel-Anti-Inflammatory-Peptide-As-aExploring a Novel Anti-Inflammatory Peptide As a Potential ...
Results: RLS-0071 significantly improves the survival of mice in multiple in vivo models of aGVHD, both when treatment is used to prevent the ...
Study Details | NCT06343792 | Safety, PK, PD, Dosing, ...
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease (AURORA).
4.
ctsearchsupport.org
ctsearchsupport.org/clinical-trials/safety-pk-pd-dosing-and-efficacy-of-rls-0071for-the-treatment-of-hospitalized-patients-with-steroid-refractory-acute-graft-versus-host-diseaseA drug, RLS-0071 , alone or with ruxolitinib, to treat acute ...
If the combination of RLS-0071, alone or with ruxolitinib , is safe and works well to treat acute GVHD that is refractory to steroids.
EMA Grants Orphan Drug Designation to Pegtarazimod for ...
Pegtarazimod has received orphan drug designation from the European Medicines Agency for the management of graft-vs-host disease.
6.
gvhdhub.com
gvhdhub.com/medical-information/rls-0071-pegtarazimod-granted-orphan-drug-designation-by-the-emaRLS-0071 (pegtarazimod) granted orphan drug ...
On August 21, 2025, RLS-0071 (pegtarazimod) received EMA orphan drug designation for the treatment of GvHD based on phase II study data in ...
ReAlta Life Sciences begins trial of graft-versus-host ...
The primary goals of the study are to evaluate the safety and overall response rate in patients who are given RLS-0071. September 24, 2024.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.